A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine
Phase 1
Completed
- Conditions
- Hepatitis BVaccine-Preventable Diseases
- Interventions
- Biological: CVI-HBV-002
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- CHA Vaccine Institute Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06147895
- Locations
- 🇰🇷
CHA University Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
Phase 1
Recruiting
- Conditions
- Vaccine-Preventable DiseasesHerpes Zoster
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- CHA Vaccine Institute Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06137755
- Locations
- 🇰🇷
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of
🇰🇷Bundang CHA General Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: CVI-HBV-002Biological: Normal Saline(placebo)
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- CHA Vaccine Institute Co., Ltd.
- Target Recruit Count
- 134
- Registration Number
- NCT04289987
- Locations
- 🇰🇷
Chung-ang University Hospital, Seoul, Dongjak-gu, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
🇰🇷The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: CVI-HBV-002
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- CHA Vaccine Institute Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT02693652
- Locations
- 🇰🇷
Bundang CHA General Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: CVI-HBV-001Biological: Conventional Hepatitis B vaccine (20 μg)
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- CHA Vaccine Institute Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT02692170
© Copyright 2025. All Rights Reserved by MedPath